Treatment of advanced solid tumors with immunotoxin LMB-1: an antibody linked to Pseudomonas exotoxin

Nature Medicine
L H PaiI Pastan

Abstract

Immunotoxin LMB-1 is composed of monoclonal antibody B3 chemically linked to PE38, a genetically engineered form of Pseudomonas exotoxin. B3 recognizes a carbohydrate antigen (Le(Y)) present on many human solid tumors. LMB-1 has excellent antitumor activity in nude mice bearing Le(Y)-positive tumors. We conducted a phase I study of 38 patients with solid tumors who failed conventional therapy and whose tumors expressed the Le(Y) antigen. Objective antitumor activity was observed in 5 patients, 18 had stable disease, 15 progressed. A complete remission was observed in a patient with metastatic breast cancer to supraclavicular nodes. A greater than 75% tumor reduction and resolution of all clinical symptoms lasting for more than six months was observed in a colon cancer patient with extensive retroperitoneal and cervical metastasis. Three patients (two colon, one breast cancer) had minor responses. The maximum tolerated dose of LMB-1 is 75 microgram/kg given intravenously three times every other day. The major toxicity is vascular leak syndrome manifested by hypoalbuminemia, fluid retention, hypotension and, in one case, pulmonary edema. Although immunotoxins have been evaluated in clinical studies for more than two decades, this...Continue Reading

References

Oct 1, 1991·Proceedings of the National Academy of Sciences of the United States of America·U BrinkmannI Pastan
Apr 15, 1991·Proceedings of the National Academy of Sciences of the United States of America·L H PaiI Pastan
Mar 1, 1986·Proceedings of the National Academy of Sciences of the United States of America·V S AlluredD B McKay
Jun 30, 1995·Annals of the New York Academy of Sciences·I H PastanD J Fitzgerald
Jan 6, 1993·JAMA : the Journal of the American Medical Association·L H Pai, I Pastan

❮ Previous
Next ❯

Citations

Jan 10, 2004·Urological Research·Tamara L McNealyMaurice Stephan Michel
Dec 24, 1997·Immunopharmacology·R Baluna, E S Vitetta
Jun 6, 2000·Advanced Drug Delivery Reviews·L Zardi, D Neri
Jun 6, 2000·Advanced Drug Delivery Reviews·I Pastan, R J Kreitman
Jun 6, 2000·Advanced Drug Delivery Reviews·W A Marasco, Dana Jones S
Dec 12, 1997·Biochimica Et Biophysica Acta·I Pastan
Nov 22, 1997·Current Opinion in Immunology·A M Scott, S Welt
Oct 6, 1999·Current Opinion in Immunology·R J Kreitman
Aug 17, 2012·Future Oncology·Catherine RabuLindy Durrant
May 8, 1999·The Journal of Peptide Research : Official Journal of the American Peptide Society·Q Lou, I Pastan
Sep 30, 1998·Proceedings of the National Academy of Sciences of the United States of America·E A BergerI Pastan
Oct 18, 2007·Proceedings of the National Academy of Sciences of the United States of America·Yujian ZhangIra Pastan
Dec 10, 1996·Proceedings of the National Academy of Sciences of the United States of America·I A LorimerI Pastan
Oct 10, 2006·The AAPS Journal·Robert J Kreitman
Oct 18, 2011·Clinical Cancer Research : an Official Journal of the American Association for Cancer Research·Robert J Kreitman, Ira Pastan
Nov 10, 2011·Toxins·Assaf Shapira, Itai Benhar
Apr 12, 2001·APMIS : Acta Pathologica, Microbiologica, Et Immunologica Scandinavica·J Le PenduM Clément
Feb 10, 2000·Annals of the New York Academy of Sciences·W Debinski
Aug 1, 1997·Current Opinion in Biotechnology·P Carter, A M Merchant
Jan 1, 1997·Nature Biotechnology·D J Fitzgerald
Oct 25, 2006·Annual Review of Medicine·Ira PastanRobert J Kreitman
Dec 15, 2015·Expert Opinion on Drug Delivery·Sagun ParakhAndrew M Scott
Dec 22, 2007·Expert Opinion on Drug Delivery·Michael J BrumlikTyler J Curiel
Dec 10, 2008·Expert Opinion on Biological Therapy·Thomas SchirrmannStefan Dübel
Jul 26, 2003·Expert Opinion on Biological Therapy·Shihui LiuStephen H Leppla
Apr 17, 2002·Expert Opinion on Biological Therapy·Tyler O KirbyRonald Alvarez
Feb 19, 2000·Journal of Drug Targeting·M YokoyamaK Kataoka
Jul 5, 2005·Expert Opinion on Investigational Drugs·R J Kreitman
Aug 29, 2002·Cancer Investigation·Waldemar Debinski
Feb 13, 2016·Immunological Reviews·Ronit MazorIra Pastan
Oct 3, 2007·Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer·Lee M KrugChaitanya Divgi
Apr 23, 2011·Drug Discovery Today·Swati ChoudharyRama S Verma
Oct 25, 2008·International Journal of Medical Microbiology : IJMM·Philipp Wolf, Ursula Elsässer-Beile
Mar 13, 2016·Biochimica Et Biophysica Acta·Joanne ChiaFrederic Bard

❮ Previous
Next ❯

Related Concepts

Related Feeds

Breast Invasive Carcinoma

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Breast Invasive Carcinoma (Keystone)

Invasive breast cancers indicate a spread into breast tissues and lymph nodes. Here are the latest discoveries pertaining to breast invasive carcinomas.

Related Papers

Proceedings of the National Academy of Sciences of the United States of America
C B SiegallH P Fell
Proceedings of the National Academy of Sciences of the United States of America
U BrinkmannI Pastan
European Journal of Cancer : Official Journal for European Organization for Research and Treatment of Cancer (EORTC) [and] European Association for Cancer Research (EACR)
L H Pai, I Pastan
Doklady Biological Sciences : Proceedings of the Academy of Sciences of the USSR, Biological Sciences Sections
A A LushnikovaE B Kampova-Polevaya
© 2021 Meta ULC. All rights reserved